Difference between revisions of "Combining-Lamotrigine-Carbamazepine"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| add = carbamazepine
 
| add = carbamazepine
 
| info =  
 
| info =  
| metabolites_ref = <ref name="informatorium">{{KNMP|carbamazepine}} </ref>
+
| stop =  
| stop = &nbsp;
 
 
| start =  
 
| start =  
* Start carbamazepine with a daily dose of 200 mg and increase dose based serum concentration if necessary. Check lamotrigines effect after 2 weeks of therapy and adapt dose if necessary.<ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref>
+
* Start carbamazepine with a daily dose of 200 mg and increase dose based on serum concentration if necessary. Check lamotrigine effect after 2 weeks of therapy and adapt dose if necessary.<ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> <ref name="drugscomint">
| cave = {{CombiCaLa}}
+
{{Drugscominteract|lamotrigine-with-carbamazepine-1430-0-497-0|lamotrigine|carbamazepine}}</ref>
 +
| cave = {{CombiCaLa}}  
 
}}
 
}}

Latest revision as of 16:04, 22 June 2010

Lamotrigine
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX09
PubChem 3878
PubMed Lamotrigine
Drugs.com lamotrigine
Kompas (Dutch) Lamotrigine
Wikipedia Lamotrigine
Carbamazepine
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AF01
Medscape Carbamazepine
PubChem 2554
PubMed Carbamazepine
Drugs.com carbamazepine
Kompas (Dutch) Carbamazepine
Wikipedia Carbamazepine

Adding carbamazepine to lamotrigine.

Infobord.png General information
  
Lamotrigine
  • Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
  
Carbamazepine
  • Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.
  
Lamotrigine
  
Carbamazepine

 

Eenrichtingbord.png Start carbamazepine
  
Carbamazepine
  • Start carbamazepine with a daily dose of 200 mg and increase dose based on serum concentration if necessary. Check lamotrigine effect after 2 weeks of therapy and adapt dose if necessary.[6] [7]
Nietinrijdenbord.png Stop carbamazepine
  
Carbamazepine
Letopbord.png Cave
  • Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase.[8]
  • Carbamazepine likely speeds the metabolism of lamotrigine, but the clinical significance is unclear.[9][10]
  • Lamotrigine may increase blood levels of carbamazepine metabolites, which can result in neurotoxicity (data about this are contradictory).[9][10]
  • These two agents have less significant pharmacologic interactions than do lamotrigine and valproate.[9][10]


  1. 1.0 1.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
  2. 2.0 2.1 Farmacotherapeutisch Kompas - lamotrigine (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
  3. Drugs.com lamotrigine
  4. WHO Collaborating Centre for Drug Statistics Methodology ATC=N03AF01
  5. KNMP; Informatorium Medicamentorum 2015; Monografie "carbamazepine" (Dutch)
  6. Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
  7. Interactions between lamotrigine and carbamazepine on drugs.com
  8. Koch HJ et al. Clinically relevant reduction of lamotrigine concentrations by carbamazepine. J Clin Psychiatry 2005;66:400-1
  9. 9.0 9.1 9.2 Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21
  10. 10.0 10.1 10.2 Levy RH et al, Metabolic Drug Interactions, Lippincott Williams & Wilkins, Philadelphia, 2000.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.